Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Citius Oncology, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
citiuspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Citius Oncology held its 2026 annual stockholder meeting on September 29, 2026, electing three Class II directors and ratifying the independent auditor. The strong voting support (67+ million votes for directors, 73+ million for auditor ratification) demonstrates shareholder confidence in the company's governance and leadership direction.
Key Takeaways
Dr. Eugene Holuka, Robert Smith, and Carol Webb were elected as Class II directors for three-year terms expiring in 2029
Wolf & Company, P.C. was ratified as the independent registered public accounting firm for fiscal year ending September 30, 2026
2 more takeaways
Filing Overview
What This Means
Citius Oncology, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.